95985-46-9

Basic information

• Product Name: 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-carboxyphenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-
• CAS NO: 95985-46-9
• Molecular Formula: C17H18N2O6S
• Molecular Weight: 378.406
• Mol File: 95985-46-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-carboxyphenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-carboxyphenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-(95985-46-9)
• EPA Substance Registry System: 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-carboxyphenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-(95985-46-9)

Safety Data

• Hazardous Substances Data: 95985-46-9(Hazardous Substances Data)

Upstream product

• 4697-36-3 D-carbenicillin 
• 4697-36-3 L-carbenicillin 
• 4800-94-6 carbenicillin disodium salt 
• 15231-78-4 2.2-dimethyl-5-phenyl-1,3-dioxane-4,6-dione 
• 551-16-6 6-aminopenicillanic acid 
• 17879-45-7 bis-(trimethylsilyl)acetamide 

Downstream Products

• 4697-36-3 L-carbenicillin 
• 4697-36-3 D-carbenicillin 
• 2613-89-0 phenylmalonic acid 

Relevant articles and documents

MODIFIED TNFalpha MOLECULES, DNA ENCODING SUCH MODIFIED TNFalpha MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFalpha MOLECULES AND DNA

New modified human tumour necrosis factoralpha , TNFalpha , (I) , able to generate, in humans, neutralising antibodies (Ab) to wild-type human TNFalpha (Ia): (a) has >= 1 fragment of TNF substituted by a peptide containing an immunodominant T-cell epitope, or (b) is a truncated form of (a) containing an immunodominant epitope and one or both flanking regions of TNF, including >= 1 TNFalpha B-cell epitope. The substitution causes a significant change in the amino acid (aa) sequence of any one of the strands in the front beta -sheet (fbS), any of the connecting loops and/or any of the B', I or D strands in the back beta -sheet (bbS). Also new are: (1) dimers, oligomers and multimers of (I); (2) isolated DNA (II) that encodes (I); (3) (expression) vectors containing (II); (4) hosts transformed with the expression vector, and (5) fusion proteins (FP) of (I) with an immunological adjuvant.

Enhancement of the efficacy of nifedipine by deuteration

A method of enhancing the efficiency and increasing the duration of action of drugs (e.g. dihydropyridines and anti-bacterials) and particularly of nifedipine and penicillins wherein one or more hydrogen atoms are deuterated and wherein the deuterated drug has unexpectedly improved properties when used in much lower concentrations than unmodified drug. A method for determining the identity and bioequivalency of a new drug is also disclosed wherein the molecular and isotope structure of a new drug is determined by isotope ratio mass spectrometry and compared with the molecular and isotope structure of a known human drug.

Epimerization and racemization of some chiral drugs in the presence of human serum albumin

-